109 results about "Antihyperglycemic Agents" patented technology

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The invention relates to a hypoglycemic drug and a composition, and particularly relates to a compound shown in a formula I in the specification or a solvate thereof, wherein the structure is shown in the specification. The invention further relates to a drug composition comprising the compound, and applications of the compound and the drug composition. The compound or the composition is an excellent hypoglycemic drug.

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The invention relates to a hypoglycemic medicine and a composition, and in particular relates to a compound as shown in the formula I or a solvate thereof. The structure of the composition is described in the specification. The invention further relates to a medicine composition comprising the compound and application of the medicine composition and the compound. The compound or the composition is an excellent hypoglycemic medicine.

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The invention discloses a preparation method of a cocoon sericin layer alcohol soluble substance, comprising the following steps: wetting clean cocoon shell, cocoon outer floss, waste silk or raw silk in water and carrying out degumming treatment for 1-5h under the conditions that the temperature is 110-140 DEG C and the pressure is 0.1-0.26Mpa to obtain silk degumming liquid; filtering and concentrating the silk degumming liquid to obtain concentrated sericin liquid and then adding an organic solvent for extraction; collecting supernatant and repeatedly extracting lower precipitate with the organic solvent; carrying out spray drying or vacuum freeze drying after concentrating combined supernatant to prepare powder, namely the cocoon sericin layer alcohol soluble substance; wherein, the volume ratio of the concentrated sericin liquid to the organic solvent is 1:1-9. The non-sericin component obtained by the invention has antioxidant activity, antityrosinase activity and alpha-glucosidase inhibition activity, and has wide application prospects in such aspects as cosmetics, anti-aging health care products, hypoglycemic drugs and the like.

The present invention relates to novel sulfoxide and bis-sulfoxide compounds, compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The invention belongs to the field of pharmacy of traditional Chinese medicines and natural medicines, relates to a production technology of an effective part extract of agriophyllum squarrosum total flavonoids, and use of the effective part extract of agriophyllum squarrosum total flavonoids in the field of pharmacy, and provides a production technology of an effective part extract of agriophyllum squarrosum total flavonoids capable of ensuring the curative effect of a medicament. The agriophyllum squarrosum total flavonoid extract disclosed by the invention is the effective part extract of total flavonoids, which is prepared from the dry over-ground parts of plant agriophyllum squarrosum of chenopodiaceae agriophyllum in China by separation and purification. According to the effective part extract of the agriophyllum squarrosum total flavonoids disclosed by the invention, the total flavonoid content exceeds 50% (ultraviolet method); the content of isorhamnetin-3-O-rutinoside is 5-10% (high efficiency liquid chromatography). The preparation method disclosed by the invention is economical in technology, simple and convenient, and applicable to industrial production. The effective part extract of the total flavonoids has a pharmacological effect of reducing blood sugar, can be prepared into the dosage forms, such as capsules, tablets, granules and oral liquid, and compound preparations thereof, and can be applied to treatment of diabetes mellitus.

The invention discloses a mulberry active phenolic compound and a pollution-free extraction and purification method thereof. The method comprises the steps that microwave and vapor high temperature instantaneous enzyme deactivation is carried out on fresh mulberries in sequence, then mechanical crushing, centrifugal layering, food grade acidified alcohol extraction, vacuum concentration and ultrafiltration membrane purification are carried out, and therefore a mulberry phenolic compound extracting solution with the biological activity is obtained. An organic reagent with the low concentration is adopted, mulberry crushing and phenolic compound extraction and purification are achieved under the mild condition, and the natural character and biological activity of the mulberry phenolic compound can be maintained. Compared with a conventional extraction method, the mulberry extracting solution has the higher-concentration total phenol and total anthocyanins, the extraction solution has the good color and luster and high oxidation resistance, alpha-glucosidase enzymatic inhibitory activity and food safety, and the mulberry active phenolic compound can be used as a safety raw material of antioxidant and hypoglycemic drug and health care product development. The conditions are mild, operation is convenient, and industrial production of high-activity natural products is facilitated.

Bougainvillea glabra triterpenoid saponin compounds comprise a triterpenoid saponin with a skeleton containing oleanolic acid, wherein the 3-site of the oleanolic acid is connected with 1'-site of beta-D-pyran glucuronic acid by an oxygen atom, and comprise other two derivates with the same skeleton structure; and the compound as shown in formula (I) is preferable, in the formula (I), R1 is methyl or hydrogen and R2 is hydrogen or beta-D-pyran xylose. The bougainvillea glabra triterpenoid saponin compounds 1-3 are new plant sourced hypoglycemic drugs. Pharmaceutical compositions with the compounds as active ingredients and a preparation method and application thereof in making the hypoglycemic drugs are provided.

The invention relates to application of total flavonoids of lilac daphne root extracted from a lilac daphne plant to preparation of a medicament for reducing blood sugar. The total flavonoids of lilac daphne root, which is disclosed by the invention, respectively represents remarkable activity of reducing blood sugar at each dosage; and the total flavonoids of lilac daphne root can be used for preparing a medicament or health-card food for preventing or treating hyperglycemia symptom.

The invention relates to the pharmacy field, in particular to medical application of resveratrol dimer. Pharmaceutical researches prove that the resveratrol dimer has obvious effect on inhibiting alpha-glucosaccharase, and can be used as hypoglycemic drugs, hypoglycemic health care foods or hypoglycemic foods.

The invention relates to application of total saponins in unripe siraitia grosvenorii fruit extract in preparation of an assistant hypoglycemic drug. Extract containing the total saponins with the content by weight of 60%-90% is extracted from unripe siraitia grosvenorii fruit with the growing period of 30 days-80 days, one of the effective ingredients mogroside II and mogroside III in the total saponins or a mixture of the effective ingredients mogroside II and mogroside III in the total saponins inhibits the activity of alpha-glucosidase in vitro and in vivo, the fasting blood-glucose level and the postprandial blood glucose level of a type-II diabetic mouse are lowered, and the activity of the insulin resistance index is reduced; in addition, new application of the total saponins in preparation of food or the drug for assisting in treating insulin resistance and type-II diabetes mellitus is achieved.

The present invention is one kind of medicine composition containing active matter extracted from male agaric, and its preparation process and application in preparing anticancer medicine, immunity regulating medicine, hypotensor and hypoglycemic. The medicine composition includes active matter extracted from male agaric and pharmaceutically acceptable carrier, and the active matter is mixture of polysaccharide PT1 of molecular weight 11-15 KDa and proteoglycan PT2 of molecular weight 17-23 KDa in the weight ratio of 1 to 1.5-4.

A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) (wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient.Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and / or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and / or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diseases or syndrome X.

The invention discloses a pharmaceutical composition for reducing blood sugar and a preparation method thereof. The method comprises a step of adding one or more pharmaceutically acceptable carriers or excipients to mix after mixing the components, namely ginseng and slender acanthopanax. The pharmaceutical composition for reducing blood sugar is applied to medicaments for preventing diabetes mellitus, adiposis and complications thereof. The pharmaceutical composition not only can be applied to an inhibitor of protein tyrosine phosphatase IB(PTPIB) and an insulin sensitizer for treating various diabetes mellituses, adiposis and other complications caused thereby.

The invention relates to application of an extract of oak tree leaves in preparation of a medicament for preventing and treating high blood sugar disease. The invention provides a preparation method for separating the extract from the oak tree leaves. Pharmacological experiments prove that the extract has obvious effect of reducing blood sugar. The invention also provides application of the extract in preparing a medicinal preparation for preventing and treating diabetes.

The present invention provides novel substituted chalcone derivatives which exhibit anti-hyperglycemic and anti-dyslipedemic activity. The invention also provides a method for treating type II diabetes and associated hyperlipidemic conditions in a mammal by administering the compounds of the present invention and compositions containing these derivatives.

The invention provides a diphenyl heptane compound and a preparation method and application thereof, and a pharmaceutical composition and an application thereof, and relates to the technical field ofmedicine preparation. The diphenyl heptane compound provided by the invention mainly comprises amomum tsao-ko alcohol compounds with 11 structures, and the compounds have obvious inhibitory activity on alpha-glucosidase, can form a pharmaceutical composition with a medicinal carrier or excipient, and can be used for preparing alpha-glucosidase inhibitor drugs, hypoglycemic drugs or health-care foods.

The invention discloses use of bacillus coagulans JA845 in preparing an enzyme activity inhibitor with a hypoglycemic function and relates to the field of hypoglycemic drugs. The bacillus coagulans JA845 is prepared into a fermentation supernatant, a cell-free extract and a bacterial cell metabolite, activity inhibition rates of the bacillus coagulans JA845 to alpha-glucosidase and DPP-4 are measured. Results show that a to-be-detected sample of the bacillus coagulans JA845 has an activity inhibition effect on the alpha-glucosidase and the DPP-4, the cell-free extract of the bacillus coagulans JA845 had the highest inhibition activity, such that the bacillus coagulans JA845 and / or derivatives thereof can be used for preparing the activity inhibitor of the alpha-glucosidase and the DPP-4 and a new thought is provided for preparing hypoglycemic drugs.

The invention relates to a preparation method of a medicinal plant extract and an application in pharmacy and health food thereof. The medicinal plant extract is prepared by using a medicinal plant of pandanus tectorius (the fruit of pandanus tectorius) in south of the Five Ridges as a raw material, and is prepared by extraction and separation. The preparation method comprises: extracting the pandanus tectorius with water or / and alcohol, concentrating and drying the extract liquid to obtain the extract of the invention. The extract is dissolved in water, and degreased; the extract is extracted by an organic solvent to obtain an extraction part; or the extract is treated by macroporous adsorption resin, and is eluted by water, methanol, ethanol, acetone or a 60-90% ethanol or acetone aqueous solution; the extract or extracted liquid or eluate is collected, recovered at a reduced pressure, concentrated into extract, and dried to obtain effective part of the medicinal plant extract of the invention. The traditional Chinese medicine extract is proved to have blood sugar reduction effect by various pharmacodynamic experiments, can be used to prepare drugs or health products for reducing blood sugar, and can be used to treat diabetes and related complications.

The invention belongs to the technical field of medicines, and particularly relates to an application of a frankincense pentacyclic triterpenic acid compound, pharmaceutically acceptable salt and combination containing the compound or the salt to preparation of a diabetes treating medicine. The compound and the combination thereof or the salt shows good blood glucose reducing functions for different insulin diabetes resistance animal models, and can possibly serve as an insulin sensitizing agent blood glucose reducing medicine for overcoming limitation of an existing medicine.

The invention discloses an extraction method and application of phenanthrene compounds from the overground part of Chinese yam, belonging to the technical field of separation and application of the active components of the overground part of Chinese yam. According to a technical scheme in the invention, the method comprises the following main steps: subjecting the coarse powder of the overground part of Chinese yam to percolation and extraction with ethanol and then carrying out concentration; then extracting extract obtained in the previous step with an organic solvent; and then carrying out separation by using macroporous adsorption resin, gel and Sephadex column chromatography and other column chromatography so as to obtain the phenanthrene compounds. Four phenanthrene compounds extracted from the overground part of Chinese yam all show substantial inhibitory activities to alpha-glucosidase, and the activities are all better than the activity of the hypoglycemic agent acarbose under same conditions.

The invention relates to dendrobium loddigesii rolfe Loddigesiinols G-K as well as a preparation method and an application thereof in preparation of hypoglycemic drugs. The Loddigesiinols G-K are prepared by the steps as follows: (1), an extracting solution obtained after dendrobium loddigesii rolfe is extracted by methyl alcohol is subjected to pressure-reduction concentration so as to obtain an extract; (2), the extract is sequentially extracted by petroleum ether, ethyl acetate and n-butyl alcohol; and (3), an ethyl acetate extract is repeatedly purified with a Sephadex LH-20 gel column chromatography technology and separated with an HPLC (high performance liquid chromatography) technology, so that five active Loddigesiinols G-K are obtained. Experiments show that dendrobium loddigesii rolfe Loddigesiinols G-K can be used as a hypoglycemic drug, a hyperglycemic health care product and a drug and health care product for preventing and curing cardiovascular disease.

The invention relates to the technical field of compounds and in particular relates to a xanthone sulfonamide derivative as well as a preparation method and application thereof. The xanthone sulfonamide derivative provided by the invention has a general structural formula shown as formula I, wherein R is selected from alkyl, H-, MeO-, a halogen substituent group, AcNH-, HO- or H2N-. According to the xanthone sulfonamide derivative, a sulfuryl chloride compound and amino xanthone are used as reaction raw materials, and a series of xanthone sulfonamide derivatives with same active units are prepared through simple and convenient sulfonylation reaction and substitution reaction; the xanthone sulfonamide derivatives have relatively high alpha-glucosidase inhibition activity and can be applied to preparation of drugs for lowering blood glucose, so that more and better drug selection can be provided for patients with diabetes mellitus.

The invention belongs to the technical filed of extraction, separation and purification; the invention discloses a method for extracting, separating and purifying lyciumbarbarum polysaccharide, lyciumbarbarumglycopeptide and a hypoglycemic medicament. The lyciumbarbarumpolysaccharide has effects in enhancing immunity, preventing aging, enhancing hematopoiesis, and preventing genetic injury; the lyceum barbarum polysaccharide (LBP) is a complex polysaccharide composed of acidic heteropolysaccharide and polypeptide or protein, and has glycopeptide structure of Glycano-O-Ser; the anti-tumor effect of the lyciumbarbarumglycopeptide is completed through an extremely complex regulation and control mode: the production of liver glycogen is inhibited by interfering the expression of related enzymes and proteins, so that the effect of reducing blood sugar is achieved. LBP has a positive effect on insulin and islet cells so as to indirectly achieve the effect of reducing blood sugar, LBP does not achieve the effect of reducing blood sugar by promoting pancreas to secrete insulin, and is a very good product for treating diabetes.

The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The invention relates to the technical field of biochemistry and natural products, in particular to a tea extract and a preparation method thereof. The preparation method comprises the following stepsof: crushing tea, and then adding the crushed tea into an acid solution for treatment; adding sodium chloride, glutamic acid, tyrosine and epicatechol gallate, carrying out reaction at 80-100 DEG C for 2-5 h, and carrying out filtration after the reaction is ended; and carrying out reduced pressure distillation on filtrate to obtain a tea extract. The invention further provides a composition, which comprises 70-95 parts of the tea extract, 2-4 parts of sorbitan stearate, 0.5-2.5 parts of polysorbate, 10-15 parts of glycerol, 0.5-2 parts of xanthan gum and 500-100 parts of water. The tea extract and the composition provided by the invention have relatively good antioxidant capacity and can be developed as antioxidants. Five tea extracts from different regions provided by the embodiment ofthe invention all have relatively good antioxidant activity and are expected to be developed as potential hypoglycemic drugs.

The invention relates to a preparation method and application of a pH-sensitive plant microcapsule nano extruder, which can effectively solve the problem of treatment of diabetes mellitus, and adopts the technical scheme that the preparation method of the drug-loaded pH-sensitive plant microcapsule nano extruder comprises the following steps: adopting pollen grains which are natural, green, high in biocompatibility and sugar adsorbability; the preparation method comprises the following steps: extracting allergen-free pollen shells as a basic material through a chemical treatment method, ultrasonically stirring, selecting insulin as a hypoglycemic drug by utilizing a strong electrostatic interaction force between rich free carboxyl groups of gamma-polyglutamic acid and a large amount of amino groups of chitosan under an acidic condition, and self-assembling to prepare nanogel which is loaded in the pollen shells. According to the pH-sensitive plant microcapsule nanoparticle extruder disclosed by the invention, the medicine can be accurately positioned in the small intestine, insulin can be continuously released to play a treatment role, and the pH-sensitive plant microcapsule nanoparticle extruder is a great innovation on the microcapsule nanoparticle extruder.

The invention discloses medical application of artabsin A and B as alpha-glucosidase inhibitors and accordingly as materials for preparing antidiabetic drugs. Research results of the embodiment show that the artabsin A and B have significant inhibition effects on alpha-glucosidase, the inhibition intensities of the artabsin A and B are higher than that of a positive drug acarbose, and thus both the artabsin A and B can be used for preparing the antidiabetic drugs. Furthermore, compared with the artabsin A, the artabsin B has the significantly higher inhibition intensity on the alpha-glucosidase, the inhibition intensity of the artabsin B is 15 times or more that of the artabsin A, and thus the artabsin B is an antidiabetic drug with better prospects.